跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
H-1PV
首页
药物
H-1PV
H-1PV
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Parvovirus formulation for treating tumors
US 10624935 B2
申请人: DEUTSCHES KREBSFORSCH
优先权: 2015
US
WO
5 件公开
H-1 PV EXPRESSING RNAI EFFECTORS
EP 4323533 A1
申请人: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS
优先权: 2021
EP
US
WO
4 件公开
Use of parvovirus for eliminating cancer stem cells (CSCs)
US 9700588 B2
申请人: ROMMELAERE JEAN
优先权: 2010
EP
US
4 件公开
MODIFIED ONCOLYTIC PARVOVIRUS H-1PV WITH AN ENHANCED FITNESS AND SUPERIOR ANTICANCER ACTIVITY
EP 4335448 A1
申请人: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS
优先权: 2022
CN
EP
US
3 件公开
Modified parvovirus having enhanced anti-tumor efficacy
US 8916176 B2
申请人: DEUTSCHES KREBSFORSCH
优先权: 2010
EP
US
3 件公开
Oncolytic virotherapy for therapy of bone cancer
EP 2535055 A1
申请人: DEUTSCHES KREBSFORSCH
优先权: 2011
EP
US
3 件公开
SCALABLE PROCESS FOR ONCOLYTIC RAT PARVOVIRUS H-1 PRODUCTION AND PURIFICATION BASED ON ISOELECTRIC POINT-BASED ELIMINATION OF EMPTY PARTICLES
EP 3321357 A1
申请人: DEUTSCHES KREBSFORSCH
优先权: 2016
EP
US
2 件公开
H-1 PV EXPRESSING RNAI EFFECTORS TARGETING CDK9
EP 3327124 A1
申请人: DEUTSCHES KREBSFORSCH
优先权: 2016
CN
EP
2 件公开
Method for predicting the clinical response of oncolytic parvovirus H1 (H-1PV) treatment in a patient suspected of suffering from cancer by measuring the expression levels of laminins and/or galectins as biomarkers in a patient's sample
US 12516381 B2
申请人: DEUTSCHES KREBS FORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS
优先权: 2018
EP
US
2 件公开
Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of its capsid
US 9234183 B2
申请人: DEUTSCHES KREBSFORSCH
优先权: 2013
US
2 件公开
第 1 / 2 页
上一页
下一页
药物
反馈